What АРТОКСАН Treats: Main Uses and Benefits

АРТОКСАН (Tenoxicam) is considered relevant for symptomatic management across domains involving inflammatory and degenerative disorders. As an anti-inflammatory and analgesic agent, it is commonly used to help with conditions where symptoms related to physical discomfort create noticeable physiological strain. The medicine is relevant for the symptomatic treatment of conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

The medicine is also commonly used when symptoms associated with acute or episodic changes intensify, which includes tendinitis, bursitis, and the intense inflammation of acute gouty arthritis, as well as managing anticipated post-operative pain and the discomfort of primary dysmenorrhea.

In situations where patients experience persistent joint pain, stiffness, and localized swelling, АРТОКСАН supports the patient during difficult episodes by easing distress and assists with maintaining functional stability during periods of heightened symptoms.

---

Quick Fact Block

Quick Fact: Used for Managing	Clinical Context
Inflammatory Pain (joints, tissues)	Chronic arthropathies (Osteoarthritis, Rheumatoid Arthritis) and acute exacerbations (Gout).
Acute Musculoskeletal Symptoms	Short-term symptomatic assistance for tendinitis, bursitis, and sprains.
Relevant for Easing Specific Discomfort	Post-operative pain and pain associated with primary dysmenorrhea.

---

Regulatory References

1. National Drug Information, Thailand FDA-related document

The official regulatory profile for ARTOKSAN is defined by strict rules regarding patient eligibility, primarily to prevent serious adverse outcomes related to its classification as an NSAID.

Eligibility Status	Population / Condition
Contraindicated (Must Not Use)	Patients with severe uncontrolled heart failure, severe hepatic or renal impairment, active peptic ulceration, or a history of gastrointestinal bleeding related to NSAID use.
Contraindicated (Must Not Use)	Individuals with known hypersensitivity to Tenoxicam or other NSAIDs/Aspirin that cause asthma, rhinitis, or urticaria, and patients in the third trimester of pregnancy.

Age and Special Population Restrictions

The medicine is generally designated for adult patients. It is not recommended for use in children and adolescents under 16 years of age because safety and efficacy data have not been established for this population. Use in elderly patients requires special caution; treatment must employ the lowest effective dose for the shortest duration possible, with close monitoring.

Conditional Use and Prohibitions

Patients with non-severe renal or hepatic impairment require careful functional monitoring if the medicine is prescribed. Use is not recommended for women who are breastfeeding or who are actively attempting to conceive due to labeled concerns regarding fertility impairment.

The official regulatory profile for АРТОКСАН (Tenoxicam) documents specific interaction patterns with other medicines and substances. This drug is contraindicated in patients with a history of hypersensitivity reactions, such as asthma or hives, following exposure to aspirin or any other Nonsteroidal Anti-inflammatory Drug (NSAID). Consequently, co-administration with other NSAIDs is not generally recommended due to the high risk of serious adverse effects.

A primary interaction domain is the elevated risk of bleeding and ulceration. This risk is officially noted when Tenoxicam is combined with Anticoagulants, Antiplatelet agents, Oral Corticosteroids, and Selective Serotonin-Reuptake Inhibitors (SSRIs). Furthermore, Tenoxicam can alter the clearance of co-administered drugs, potentially causing accumulation. Regulatory documentation indicates Tenoxicam may increase Lithium serum concentrations and reduce the clearance of Methotrexate.

Pharmacodynamic interactions may result in the diminution of efficacy for certain medicines, including Diuretics and Antihypertensives (such as ACE Inhibitors and ARBs). Separately, co-administration with Quinolone Antibiotics carries a documented potential for CNS excitation. Regarding timing, food intake is officially noted to delay the rate of drug absorption. Population-specific notes include the need for caution in elderly patients due to a heightened risk of renal function deterioration when used with ACE Inhibitors or ARBs. The overall interaction structure is defined by pharmacodynamic risks and the pharmacokinetic inhibition of drug clearance.

️ Molecular Targeting of the COX Pathway

The primary mechanism of АРТОКСАН (Tenoxicam) is the non-selective inhibition of the Cyclooxygenase (COX-1 and COX-2) enzymes within the Arachidonic Acid Cascade. This molecular blockade suppresses the biosynthesis of pro-inflammatory prostaglandins ( PGE2), which are chemical mediators responsible for sensitizing peripheral nociceptors and increasing local vascular permeability. The resulting physiological effect is the reduction of peripheral nociceptor sensitization and the decrease in local vascular permeability.

Cellular and Persistence Mechanisms

Tenoxicam also limits the processes associated with tissue breakdown by stabilizing lysosomal membranes within cells and inhibiting the activity of metalloproteinases, enzymes that degrade connective tissue structures. Furthermore, the molecule's long elimination half-life translates into a sustained state of enzyme inhibition at the molecular level, allowing for prolonged biochemical pathway suppression.

АРТОКСАН (Tenoxicam) is administered through both oral and parenteral routes. The medicine is available as 20 mg tablets for oral use, and as a 20 mg lyophilized powder for injection. The injectable form is intended for intramuscular (IM) or intravenous (IV) bolus administration and is typically reserved for initiating treatment over a short period (generally one to two days) before transitioning the patient to the oral dosage form.

The standard regimen for most indications is a single daily dose of 20 mg. To maintain consistent therapeutic levels, the dose should be administered at the same time each day. Specific acute conditions may require different initial dosing patterns; for example, postoperative pain may utilize a higher dose of 40 mg once daily for a maximum of five days. The lyophilized powder must be reconstituted with the supplied sterile water prior to administration, and injection should be by bolus, as infusion use is not recommended.

For oral administration, tablets must be swallowed whole and are generally instructed to be taken with liquid, preferably during or immediately after a meal. Duration of use is condition-dependent; treatment for acute musculoskeletal disorders should generally not exceed 7 to 14 days. Dose adjustment principles apply to specific populations: the approach for older adults involves the use of the lowest effective dose, and no dosage recommendations have been established for pediatric patients.

Research evidence / Overview of Studies for АРТОКСАН

---

Evidence for Chronic Joint and Musculoskeletal Conditions

The examination of АРТОКСАН (Tenoxicam) in conditions characterized by fluctuating or episodic manifestations, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, was studied for extensive research. Studies conducted for these conditions included multicenter Randomized Controlled Trials (RCTs), many of which were double-blind and comparative, alongside analyses of large long-term observational data. The research examined outcomes related to physical discomfort and daily functioning, using standardized tools to measure pain intensity, the duration of joint stiffness, and overall functional status.

These long-term studies, which sometimes monitored patients for periods of up to one to two years, reported patterns observed in the studies related to sustained use and patient status maintenance over time. Research describes patterns observed in the studies related to symptom measurement across the observed populations with chronic conditions. It is important to understand that while the evidence base is extensive, some of the initial comparative trials were conducted with relatively smaller patient groups, limiting the ability to describe minor differences between agents in comparative trials.

---

Evidence for Acute Pain and Short-Term Inflammation

Research has been conducted for АРТОКСАН in conditions associated with acute or disruptive episodes, such as Acute Gouty Arthritis, tendinitis, bursitis, and general soft tissue injuries. The evidence includes short-term clinical trials which compared the medicine against a placebo or other active pain management agents, focusing on episodes where symptoms become more noticeable.

In these studies, researchers monitored patient-reported outcomes describing perceived discomfort and objective changes in mobility (range of motion) over defined time intervals. Evidence for certain specialized applications, such as local injection formulations, remains limited or inconsistent, with some studies reporting patterns of observed symptom changes that were not consistently established for long-term patient outcomes.

---

Areas of Ongoing Research and Uncertainty

Research highlights what is known and what is still uncertain about this medicine. Sample sizes were modest in some of the older, foundational studies, meaning the results apply only to the populations studied. Evidence quality varies across studies, particularly for specialized uses like local injection for soft tissue injuries, where findings were mixed or follow-up durations were limited. Comparative evidence against some newer therapeutic agents is still emerging, and data for certain groups or very specific types of joint inflammation remain insufficient.

Key Studies & References

1. National Drug Information (Thailand) - Document on Tenoxicam Uses

Common questions about АРТОКСАН (FAQ)

Q: What is the active substance in АРТОКСАН and how does it work?

АРТОКСАН contains the active substance tenoxicam. According to official product information, tenoxicam belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It is described as having anti-inflammatory (reducing swelling and irritation), analgesic (pain-relieving), and antipyretic (fever-reducing) effects.

---

Q: For what medical conditions is АРТОКСАН typically prescribed?

Regulatory documents state that АРТОКСАН is prescribed for relief in various painful and inflammatory conditions. This includes joint disorders such as rheumatoid arthritis and osteoarthritis, as well as soft-tissue disorders like tendinitis and bursitis. It is also indicated for extra-articular conditions, such as lumbago (lower back pain).

---

Q: Can АРТОКСАН be used for both acute (short-term) and chronic (long-term) pain?

Official product information indicates that АРТОКСАН can be used for both acute and chronic conditions. Examples include short-term treatment of acute gout and the management of chronic inflammatory diseases like rheumatoid arthritis. The specific duration of treatment is determined by a healthcare professional based on the patient's individual condition.

---

Q: How quickly does АРТОКСАН start to relieve pain?

According to the official prescribing information, tenoxicam, the active substance in АРТОКСАН, is rapidly absorbed after administration. The onset of therapeutic action, meaning the start of pain relief, is typically observed relatively quickly following administration, according to official data.

---

Q: Does АРТОКСАН require a prescription from a doctor?

Regulatory documents classify tenoxicam as a prescription-only medicine (POM). Therefore, a valid prescription from a healthcare professional is necessary for АРТОКСАН.

How to Store and Dispose of ARTOXAN (Tenoxicam)

Storage and disposal must strictly follow the official regulatory guidelines to maintain the medicine's stability and ensure environmental safety.

---

Storage Requirements

ARTOXAN preparations must be stored out of the sight and reach of children.

• Temperature: Store the medicine at room temperature, typically not exceeding 25 C to 30 C, depending on the formulation.
• Protection: The product must be kept in the original container to protect it from light and moisture.
• Injection Stability: The powder for injection must be reconstituted and used immediately; delayed use is not supported by the official label.

Disposal Instructions

Do not dispose of ARTOXAN via wastewater or regular household trash. Unused or expired medicine must be discarded according to local, regional, and national pharmaceutical waste regulations.